Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of$16.59RVMD · NASDAQ-GS
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $11.58M | $35.38M | $29.39M | $42.98M | $50.04M | $20.16M |
| Research & Development | $987.33M | $592.23M | $423.14M | $253.07M | $186.95M | $132.25M | $91.75M | $51.08M |
| Selling, General & Administrative | $195.04M | $97.30M | $75.62M | $40.59M | $30.45M | $21.43M | $12.41M | $9.41M |
| Operating Expenses | $1.18B | $689.52M | $498.76M | $293.66M | $217.40M | $153.68M | $104.16M | $60.49M |
| Operating Income | -$1.18B | -$689.52M | -$487.19M | -$258.28M | -$188.01M | -$110.70M | -$54.12M | -$40.33M |
| Interest Expense | — | — | — | $0.00 | $12.00K | $71.00K | $106.00K | $116.00K |
| Other Income / (Expense) | $51.07M | $88.68M | $47.29M | $9.15M | $917.00K | $2.17M | $2.08M | -$1.46M |
| Income Before Taxes | -$1.13B | -$600.85M | -$439.89M | -$249.13M | -$187.09M | -$108.53M | -$52.04M | -$41.79M |
| Provision for Income Taxes | $0.00 | -$753.00K | -$3.52M | -$420.00K | $0.00 | -$371.00K | -$4.37M | — |
| Net Income | -$1.13B | -$600.00M | -$436.00M | -$249.00M | -$187.00M | -$108.16M | -$47.66M | -$41.79M |
| Basic EPS | -$5.95 | -$3.58 | -$3.86 | -$3.08 | -$2.57 | -$2.01 | — | — |
| Diluted EPS | -$5.95 | -$3.58 | -$3.86 | -$3.08 | -$2.57 | -$2.01 | — | — |
| Basic Shares Outstanding | 190.13M | 167.74M | 113.15M | 80.63M | 72.81M | 54.87M | — | — |
| Diluted Shares Outstanding | 190.13M | 167.74M | 113.15M | 80.63M | 72.81M | 54.87M | — | — |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | -$7.92 | -$8.55 | -$7.20 | 11 | ↑2 ↓2 |
| Dec 2027 | -$4.86 | -$10.74 | $0.96 | 10 | ↑4 ↓0 |
| Dec 2028 | $0.78 | -$4.51 | $6.79 | 5 | ↑2 ↓0 |
| Dec 2029 | $7.17 | -$1.68 | $11.85 | 3 | ↑2 ↓0 |
